Crypto News

5 days ago

Legend Biotech (LEGN) Stock: CARVYKTI Revenue Soars 66% in Q4 with 2026 Profit Target

Stocks

Legend Biotech (LEGN) stock analysis: CARVYKTI Q4 sales surge 66% to $555M, manufacturing scales up, and company targets enterprise profitability by 2026.

The post Legend Biotech (LEGN) Stock: CARVYKTI Revenue Soars 66% in Q4 with 2026 Profit Target appeared first on Blockonomi.

Source: Blockonomi →

Related News

Trending Category

$ADA$ARB$BITF$BLSH$BMNR$BONK$DBKSF$ENA$LUXFF$MATH$MTT token$NIGHT$PUMP$RAY$S$SEA$SOL$SPACE token$SPTZ$SPX

Latest News